Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Fulgent Genetics, Inc. and its officers or directors [1] Group 1: Investigation Details - The investigation is prompted by claims from investors of Fulgent Genetics, Inc. [1] - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1] Group 2: Recent Developments - On February 28, 2025, Fulgent disclosed receiving a civil investigative demand from the U.S. Department of Justice concerning potential false claims under the Uninsured Program [3] - Following this disclosure, Fulgent's stock price decreased by $0.41 per share, or 2.61%, closing at $15.28 per share on March 3, 2025 [3] Group 3: Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in the field [4] - The firm has successfully recovered numerous multimillion-dollar damages awards for victims of securities fraud and corporate misconduct [4]

Key Takeaways CI is up 14.7% YTD, outperforming the industry's 29.1% drop, backed by dual-segment strength. Evernorth revenues rose 16% to $53.7B in Q1 2025; Cigna Healthcare grew 9% year over year. CI faces margin pressure from rising benefit costs and carries $26.5B in long-term debt.The Cigna Group (CI) , a longstanding global health company, continues to offer a variety of health solutions and insurance products. It operates through two main divisions: Cigna Healthcare and Evernorth Health Services. T ...

Key Takeaways Paylocity maintained client stability in Q3 despite macro pressures and high interest rates. Expanded AI tools and integrations boosted average revenue per client and cross-sell potential. Q3 revenues rose 13% to $454.6M, beating guidance and prompting an upward revision to the FY2025 outlook.Paylocity Holding (PCTY) shares have lost 6.8% in the trailing three months, underperforming the Zacks Computer and Technology sector, the S&P 500 index and the Zacks Internet - Software industry’s grow ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas’ registration statement for the initial public offering held on or about September 13, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth?Moderna (NASDAQ: MRNA ) shares are down over 35% year-to-date, over 80% on a one-year basis, and since reaching their pandemic era high of over $450 per share, they are down 94%.The group is for both novice and expe ...

Group 1 - The article discusses the geopolitical landscape between China and the U.S., indicating that it is not a simple stalemate, despite market fears [1] - Oliver Rodzianko is the Founder and CEO of Invictus Origin, an investment management firm launched in May 2025, focusing on high-alpha strategies [1] - Invictus Origin's flagship portfolio, the Nasdaq High-Alpha Black Swan Portfolio, aims to outperform the Nasdaq-100 while maintaining approximately 20% in cash reserves for downside protection [1] Group 2 - Oliver Rodzianko has extensive experience as a macro-focused investment analyst, specializing in sectors such as technology, semiconductors, artificial intelligence, and energy [1] - The investment process at Invictus Origin integrates U.S. market specialization with a comprehensive understanding of international markets [1] - The firm aims to deliver durable outperformance by navigating market dislocations and intrinsic value cycles [1]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Apple Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - Apple announced an indefinite delay in updates to its Siri digital assistant, impacting investor sentiment and leading to a significant drop in stock price [3] - Morgan Stanley analyst Erik Woodring lowered Apple's price target due to the delay in Siri features, which could affect iPhone upgrade cycles [4] Company Developments - Apple has postponed the release of certain Siri features that were initially expected in June 2024, now anticipated to be released in the coming year [3] - Following the announcement of the delay, Apple's stock price fell by $11.59, or 4.85%, closing at $227.48 on March 10, 2025 [3] - The stock price further declined by $11.16, or 5.05%, to close at $209.68 on March 13, 2025, after Morgan Stanley's report [5] Analyst Insights - Morgan Stanley's report indicated that approximately 50% of iPhone owners who did not upgrade to the iPhone 16 cited the delay in Siri features as a reason for their decision [4] - The lowered price target from Morgan Stanley went from $275 to $252, reflecting concerns over the impact of Siri's delays on future iPhone sales [4]

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Photronics, Inc. (“Photronics” or the “Company”) (NASDAQ: PLAB).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Photronics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 2 ...

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Hallador Energy Company (“Hallador” or the “Company”) (NASDAQ: HNRG).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Hallador and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May ...

Core Insights - PepsiCo's international business is crucial for its global strategy and long-term growth, achieving 5% organic revenue growth in Q1 2025, marking 16 consecutive quarters of mid-single-digit growth despite geopolitical and macroeconomic challenges [1][4] - The international segment contributed nearly 40% of PepsiCo's total net revenues and core operating profit in 2024, with a portfolio valued at approximately $37 billion [1][4] International Business Performance - The international beverages business led growth with 11% organic growth in Q1 2025, driven by strong demand in markets such as China, India, Egypt, Turkey, Mexico, Brazil, the U.K., and Australia [2][8] - The international convenient foods business grew 2% organically, supported by strong performance in Brazil, Egypt, India, and Turkey, along with snack share gains in China, South Africa, Poland, and Thailand [2] Future Strategy - PepsiCo plans to enhance its global presence by deepening localization efforts, adapting product offerings to regional tastes, and expanding channel reach [3][4] - Investments in automation, digitalization, and standardization are aimed at increasing productivity and freeing up capital for reinvestment in commercial initiatives and innovation [3] Competitive Landscape - Key competitors in the international market include The Coca-Cola Company and Monster Beverage, both of which compete with PepsiCo in several key markets [5][6] - Coca-Cola's international strategy focuses on being a "Total Beverage Company," with significant market share in Latin America, Western Europe, and the Asia-Pacific region [6] - Monster Beverage is expanding its international footprint, contributing approximately 39.6% of its total revenues in Q1 2025, with a focus on key markets like China and India [7][9] Financial Performance and Valuation - PepsiCo's shares have declined approximately 13.5% year-to-date, contrasting with the industry's growth of 6.9% [12] - The forward price-to-earnings ratio for PepsiCo is 16.33X, below the industry average of 18.59X [13] - The Zacks Consensus Estimate for PepsiCo's 2025 earnings indicates a year-over-year decline of 3.6%, while the 2026 estimate suggests a 5.4% increase [14]